Anika Therapeutics (NASDAQ: ANIK) CEO adds shares via RSU vesting and award

Rhea-AI Filing Summary

Anika Therapeutics President and CEO Stephen D. Griffin reported equity compensation activity tied to vesting restricted stock units. On March 14, 2026, he exercised 12,824 restricted stock units, receiving 12,824 shares of common stock at a stated exercise price of $0.00 per share.

On the same date, he also acquired 6,412 shares of common stock as a grant or award, and 5,944 shares were withheld by the company at $14.20 per share to cover tax obligations related to vested RSUs and PSUs. Following these transactions, Griffin directly owns 23,963 shares of Anika Therapeutics common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Griffin Stephen D.

(Last) (First) (Middle)

C/O ANIKA THERAPEUTICS, INC.

32 WIGGINS AVENUE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Anika Therapeutics, Inc. [ ANIK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/14/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/14/2026		M		12,824	A	(1)	23,495	D
Common Stock	03/14/2026		A		6,412(2)	A	$0	29,907	D
Common Stock	03/14/2026		F		5,944(3)	D	$14.2	23,963	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	03/14/2026		M			12,824	(4)	(4)	Common Stock	12,824	$0	25,649	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock.

2. On March 14, 2025, the Reporting Person was granted 19,236 performance-based phantom RSUs ("PSUs") with vesting contingent upon the achievement of pre-established performance and strategic targets. This transaction represents the first vesting installment of such PSU award.

3. Reflects an aggregate of 5,944 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs and PSUs that vested on March 14, 2026.

4. On March 14, 2025, the Reporting Person was granted 38,473 RSUs vesting in three equal annual installments beginning on March 14, 2026. This transaction reflects the first vesting installment of such RSU award.

	/s/ Stephen D. Griffin	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Anika Therapeutics (ANIK) report for CEO Stephen D. Griffin?

Anika Therapeutics reported that CEO Stephen D. Griffin exercised 12,824 restricted stock units into common shares, received an additional 6,412-share stock award, and had 5,944 shares withheld to satisfy tax obligations related to these vestings, all on March 14, 2026.

How many Anika Therapeutics (ANIK) shares does the CEO hold after the latest Form 4?

After the reported transactions, CEO Stephen D. Griffin directly holds 23,963 shares of Anika Therapeutics common stock. This figure reflects RSU and PSU vesting, the associated stock grant, and shares withheld by the company to cover related tax obligations.

Were Stephen D. Griffin’s Anika (ANIK) transactions open-market buys or compensation-related?

The transactions were compensation-related, not open-market purchases. They include exercising 12,824 restricted stock units, receiving a 6,412-share stock award, and a 5,944-share disposition classified as tax withholding to satisfy obligations on vested RSUs and PSUs.

What is the significance of the 5,944 Anika Therapeutics (ANIK) shares classified as code F?

The 5,944 shares coded F represent stock retained by Anika Therapeutics to cover tax withholding obligations for Stephen D. Griffin. They are not an open-market sale but shares withheld by the issuer in connection with RSU and PSU vesting on March 14, 2026.

What performance-based and time-based equity awards are referenced in Anika (ANIK) CEO’s Form 4 footnotes?

Footnotes describe a 19,236-share performance-based phantom RSU grant and a 38,473-share RSU grant awarded on March 14, 2025. The reported Form 4 transactions reflect the first vesting installments of these PSU and RSU awards, subject to performance and time-based conditions.